GlassScriptPhysician profile
Muhammad R Ishaque
NPI 1255528949
$2,298.47
in general payments reported to CMS, 2019-2025
14 companies · $957 in 2025
The $957 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $225 · 2021: $36.17 · 2022: $245 · 2023: $521 · 2024: $188 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932 · Travel and Lodging: $665 · Education: $68.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.89 |
| Travel and Lodging | $664.91 |
| Education | $68.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $910.61 | 2025 | Renal - Acute, Renal - Pd |
| Fresenius USA Marketing, INC. | $384.63 | 2020-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $287.76 | 2019-2025 | Lokelma, Farxiga |
| Aurinia Pharma U.S., INC. | $127.01 | 2022-2023 | Lupkynis |
| Amgen INC. | $110.97 | 2019-2023 | Tavneos |
| Horizon Therapeutics Plc | $96.44 | 2020-2023 | Krystexxa |
| Akebia Therapeutics INC | $89.78 | 2022-2024 | Vafseo |
| Vifor Pharma, INC. | $66.70 | 2023-2024 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Glaxosmithkline, LLC. | $45.18 | 2022-2023 | Benlysta |
| Kyowa Kirin, INC. | $40.10 | 2024 | Crysvita |
| Travere Therapeutics, INC. | $32.22 | 2023 | |
| Calliditas Therapeutics US INC. | $26.34 | 2023 | Tarpeyo |
| Lilly USA, LLC | $19.53 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ishaque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.